Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

AdaptHealth

Nasdaq:AHCO
Snowflake Description

Exceptional growth potential with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AHCO
Nasdaq
$1B
Imp Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

AdaptHealth Corp., together with its subsidiaries, provides home healthcare equipment, supplies, and related services in the United States. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • AdaptHealth has significant price volatility in the past 3 months.
AHCO Share Price and Events
7 Day Returns
20.8%
NasdaqCM:AHCO
-4%
US Healthcare
-4.1%
US Market
1 Year Returns
-
NasdaqCM:AHCO
-4.6%
US Healthcare
-14.9%
US Market
AHCO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AdaptHealth (AHCO) 20.8% 8% 65.8% - - -
US Healthcare -4% -12.9% -18.2% -4.6% 12.3% 13.1%
US Market -4.1% -19.1% -23.4% -14.9% 3.5% 14.5%
1 Year Return vs Industry and Market
  • No trading data on AHCO.
  • No trading data on AHCO.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is AdaptHealth undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of AdaptHealth to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for AdaptHealth.

NasdaqCM:AHCO Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:AHCO
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.66
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.656 (1 + (1- 21%) (31.73%))
0.88
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.88
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.88 * 5.44%)
6.53%

Discounted Cash Flow Calculation for NasdaqCM:AHCO using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for AdaptHealth is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqCM:AHCO DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.53%)
2020 33.72 Est @ -18.75% 31.65
2021 29.47 Est @ -12.6% 25.97
2022 27.02 Est @ -8.3% 22.35
2023 25.59 Est @ -5.29% 19.88
2024 24.78 Est @ -3.18% 18.06
2025 24.36 Est @ -1.7% 16.67
2026 24.19 Est @ -0.67% 15.54
2027 24.21 Est @ 0.05% 14.60
2028 24.34 Est @ 0.56% 13.78
2029 24.56 Est @ 0.91% 13.05
Present value of next 10 years cash flows $191.00
NasdaqCM:AHCO DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $24.56 × (1 + 1.74%) ÷ (6.53% – 1.74%)
$522.25
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $522.25 ÷ (1 + 6.53%)10
$277.55
NasdaqCM:AHCO Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $191.00 + $277.55
$468.55
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $468.55 / 73.82
$6.35
NasdaqCM:AHCO Discount to Share Price
Calculation Result
Value per share (USD) From above. $6.35
Current discount Discount to share price of $18.15
= -1 x ($18.15 - $6.35) / $6.35
-185.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of AdaptHealth is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AdaptHealth's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AdaptHealth's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:AHCO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.66
NasdaqCM:AHCO Share Price ** NasdaqCM (2020-04-02) in USD $18.15
United States of America Healthcare Industry PE Ratio Median Figure of 45 Publicly-Listed Healthcare Companies 20.24x
United States of America Market PE Ratio Median Figure of 2,944 Publicly-Listed Companies 12.5x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AdaptHealth.

NasdaqCM:AHCO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:AHCO Share Price ÷ EPS (both in USD)

= 18.15 ÷ -0.66

-27.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AdaptHealth is loss making, we can't compare its value to the US Healthcare industry average.
  • AdaptHealth is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does AdaptHealth's expected growth come at a high price?
Raw Data
NasdaqCM:AHCO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -27.3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
51.5%per year
United States of America Healthcare Industry PEG Ratio Median Figure of 32 Publicly-Listed Healthcare Companies 1.52x
United States of America Market PEG Ratio Median Figure of 2,008 Publicly-Listed Companies 0.91x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AdaptHealth, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AdaptHealth's assets?
Raw Data
NasdaqCM:AHCO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-0.36
NasdaqCM:AHCO Share Price * NasdaqCM (2020-04-02) in USD $18.15
United States of America Healthcare Industry PB Ratio Median Figure of 94 Publicly-Listed Healthcare Companies 2.31x
United States of America Market PB Ratio Median Figure of 5,142 Publicly-Listed Companies 1.22x
NasdaqCM:AHCO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:AHCO Share Price ÷ Book Value per Share (both in USD)

= 18.15 ÷ -0.36

-51.02x

* Primary Listing of AdaptHealth.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AdaptHealth has negative assets, we can't compare the value of its assets to the US Healthcare industry average.
X
Value checks
We assess AdaptHealth's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. AdaptHealth has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is AdaptHealth expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
51.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AdaptHealth expected to grow at an attractive rate?
  • AdaptHealth's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • AdaptHealth's earnings growth is expected to exceed the United States of America market average.
  • AdaptHealth's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:AHCO Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:AHCO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 51.5%
NasdaqCM:AHCO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 20.4%
United States of America Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 6.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:AHCO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:AHCO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,316 192 134 1
2022-12-31 1,099 169 68 2
2021-12-31 932 168 49 3
2020-12-31 799 92 36 2
2020-04-03
NasdaqCM:AHCO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 530 60 -15
2019-09-30 489 68 -8
2019-06-30 454 72 8
2019-03-31 400 70 16
2018-12-31 345 68 23
2017-12-31 193 46 10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AdaptHealth's earnings are expected to grow significantly at over 20% yearly.
  • AdaptHealth's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:AHCO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from AdaptHealth Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:AHCO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.77 1.77 1.77 1.00
2022-12-31 1.20 1.31 1.10 2.00
2021-12-31 0.92 0.96 0.89 2.00
2020-12-31 0.74 0.90 0.57 2.00
2020-04-03
NasdaqCM:AHCO Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.66
2019-09-30 -33.05
2019-06-30 32.84
2019-03-31 64.08
2018-12-31 1.95
2017-12-31 77.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • AdaptHealth is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess AdaptHealth's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AdaptHealth has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has AdaptHealth performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AdaptHealth's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AdaptHealth does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare AdaptHealth's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AdaptHealth's 1-year growth to the US Healthcare industry average as it is not currently profitable.
Earnings and Revenue History
AdaptHealth's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AdaptHealth Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:AHCO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 529.64 -15.00 51.62
2019-09-30 488.76 -8.07 40.00
2019-06-30 454.46 8.02 38.80
2019-03-31 399.87 15.64 31.63
2018-12-31 345.28 23.26 23.85
2017-12-31 192.56 9.89 12.29
2016-12-31 174.32 -3.79 11.40

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AdaptHealth has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • AdaptHealth used its assets less efficiently than the US Healthcare industry average last year based on Return on Assets.
  • It is difficult to establish if AdaptHealth improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AdaptHealth's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AdaptHealth has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is AdaptHealth's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AdaptHealth's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AdaptHealth is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AdaptHealth's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of AdaptHealth's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • AdaptHealth has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AdaptHealth Company Filings, last reported 3 months ago.

NasdaqCM:AHCO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -29.25 405.17 76.88
2019-09-30 -136.70 430.17 8.82
2019-06-30 -134.89 395.89 2.16
2019-03-31 -134.89 395.89 2.16
2018-12-31 102.77 134.58 26.13
2017-12-31 -0.64 54.78 4.27
2016-12-31
  • AdaptHealth has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if AdaptHealth's debt level has increased considering it has negative shareholder equity.
  • Debt is not well covered by operating cash flow (14.9%, less than 20% of total debt).
  • AdaptHealth is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess AdaptHealth's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AdaptHealth has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is AdaptHealth's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AdaptHealth dividends.
If you bought $2,000 of AdaptHealth shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AdaptHealth's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AdaptHealth's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:AHCO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 1.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1941 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:AHCO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-03

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AdaptHealth has not reported any payouts.
  • Unable to verify if AdaptHealth's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AdaptHealth's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AdaptHealth has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess AdaptHealth's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AdaptHealth afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AdaptHealth has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of AdaptHealth's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Luke McGee
COMPENSATION $8,064,521
AGE 35
TENURE AS CEO 8.3 years
CEO Bio

Mr. Luke McGee serves as the Chief Executive Officer of QMES Holdings LLC since November 11, 2017. Mr. McGee serves as the Chief Executive Officer of AdaptHealth Corp. since 2012 and its Director since November 8, 2019. Mr. McGee founded AdaptHealth in conjunction with Quadrant Management in 2012. Prior to partnering with Quadrant, Mr. McGee was in the investment banking group at Deutsche Bank and before that Merrill Lynch. He holds a bachelor’s degree in Economics from Duke University.

CEO Compensation
  • Luke's compensation has increased whilst company is loss making.
  • Luke's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the AdaptHealth management team in years:

4.5
Average Tenure
44
Average Age
  • The tenure for the AdaptHealth management team is about average.
Management Team

Luke McGee

TITLE
CEO & Director
COMPENSATION
$8M
AGE
35
TENURE
8.3 yrs

Joshua Parnes

TITLE
President & Director
COMPENSATION
$6M
AGE
40
TENURE
2.7 yrs

Christopher Joyce

TITLE
General Counsel
COMPENSATION
$2M
AGE
55
TENURE
2.3 yrs

Gregg Holst

TITLE
Chief Financial Officer
AGE
60
TENURE
6.3 yrs

Shaw Rietkerk

TITLE
Chief Operating Officer
AGE
44
Board of Directors Tenure

Average tenure and age of the AdaptHealth board of directors in years:

0.4
Average Tenure
63
Average Age
  • The average tenure for the AdaptHealth board of directors is less than 3 years, this suggests a new board.
Board of Directors

Richard Barasch

TITLE
Independent Chairman of the Board
COMPENSATION
$119K
AGE
65
TENURE
0.4 yrs

Luke McGee

TITLE
CEO & Director
COMPENSATION
$8M
AGE
35
TENURE
0.4 yrs

Joshua Parnes

TITLE
President & Director
COMPENSATION
$6M
AGE
40
TENURE
0.4 yrs

Alan Quasha

TITLE
Independent Director
COMPENSATION
$79K
AGE
70
TENURE
0.4 yrs

Terence Connors

TITLE
Independent Director
COMPENSATION
$78K
AGE
63
TENURE
0.4 yrs

Susan Weaver

TITLE
Independent Director
COMPENSATION
$72K
AGE
58
TENURE
2.2 yrs

Dale Wolf

TITLE
Independent Director
COMPENSATION
$66K
AGE
65
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by AdaptHealth individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
23. Mar 20 Buy Dale Wolf Individual 19. Mar 20 19. Mar 20 500 $10.50 $5,250
20. Dec 19 Buy Dale Wolf Individual 18. Dec 19 18. Dec 19 10,000 $10.20 $102,000
X
Management checks
We assess AdaptHealth's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AdaptHealth has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

AdaptHealth Corp., together with its subsidiaries, provides home healthcare equipment, supplies, and related services in the United States. The company focuses primarily on providing sleep therapy equipment, supplies, and related services, including CPAP and bi PAP services to individuals suffering from obstructive sleep apnea; home medical equipment (HME) to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME medical devices and supplies on behalf of chronically ill patients with diabetes care, wound care, urological, ostomy, and nutritional supply needs. It services beneficiaries of Medicare, Medicaid, and commercial payors. The company is based in Plymouth Meeting, Pennsylvania.

Details
Name: AdaptHealth Corp.
AHCO
Exchange: NasdaqCM
Founded:
$1,339,746,206
$775,938,254
73,815,218
Website: http://www.adapthealth.com
Address: AdaptHealth Corp.
220 West Germantown Pike,
Suite 250,
Plymouth Meeting,
Pennsylvania, 19462,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM AHCO Class A Common Stock Nasdaq Capital Market US USD 11. Nov 2019
Number of employees
Current staff
Staff numbers
2,590
AdaptHealth employees.
Industry
Health Care Distributors
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 05:19
End of day share price update: 2020/04/02 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/03/06
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.